Yi-Shin Chang, Kai Huang, Jessica M Lee, Christen L Vagts, Christian Ascoli, Md-Ruhul Amin, Mahmood Ghassemi, Claudia M Lora, Russell Edafetanure-Ibeh, Yue Huang, Ruth A Cherian, Nandini Sarup, Samantha R Warpecha, Sunghyun Hwang, Rhea Goel, Benjamin A Turturice, Cody Schott, Montserrat Hernandez, Yang Chen, Julianne Jorgensen, Wangfei Wang, Mladen Rasic, Richard M Novak, Patricia W Finn, David L Perkins
BACKGROUND: End-stage renal disease (ESRD) patients experience immune compromise characterized by complex alterations of both innate and adaptive immunity, and results in higher susceptibility to infection and lower response to vaccination. This immune compromise, coupled with greater risk of exposure to infectious disease at hemodialysis (HD) centers, underscores the need for examination of the immune response to the COVID-19 mRNA-based vaccines. METHODS: The immune response to the COVID-19 BNT162b2 mRNA vaccine was assessed in 20 HD patients and cohort-matched controls...
April 24, 2024: ELife